On November 21, 2024, Robert Lechleider, Chief Medical Officer at Immunome Inc, purchased 15,805 shares of the company. Following this transaction, the insider now owns a total of 15,805 shares. The transaction details are available in the SEC Filing.
Immunome Inc (IMNM, Financial) is a biotechnology company focused on developing antibody therapeutics for cancer and infectious diseases. The company's approach leverages its proprietary discovery engine to identify novel therapeutic antibodies.
The insider's recent purchase is part of a broader trend within the company. Over the past year, there have been six insider buys and two insider sells. This indicates a general trend of insider confidence in the company's prospects.
On the day of the purchase, shares of Immunome Inc were trading at $9.48 each, resulting in a market cap of $672.229 million. This transaction reflects the insider's belief in the company's potential and aligns with the overall insider buying trend observed over the past year.
For investors, insider buying can be a signal of confidence in the company's future performance. However, it is essential to consider other factors such as the company's GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow when making investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
